NCT02648620已完成不适用
A Prospective, Multi-Center, Single-Arm Trial to Assess the Safety and Feasibility of the SurModics Drug Coated Balloon in the Treatment of Subjects With De Novo Lesions of the Femoropopliteal Artery
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 6
- 主要终点
- Peak paclitaxel plasma concentration
研究概览
简要总结
PREVEIL is a prospective, multi-center, single-arm clinical trial to assess the safety and functionality of the SurModics drug coated balloon (DCB) in the treatment of subjects with symptomatic peripheral artery disease (PAD) due to de novo stenoses of the femoral and popliteal arteries. The trial will enroll up to 15 subjects.
详细描述
PREVEIL will enroll patients presenting with angiographic evidence of significant stenosis in the femoral or popliteal arteries. All enrolled subjects will be treated with the SurVeil DCB.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must meet all of the following criteria to participate in the trial:
- •Subject is ≥ 18 years.
- •Subject has lifestyle-limiting claudication or rest pain with Rutherford classification 2, 3 or
- •Subject has provided written informed consent.
- •Subject is willing to comply with study follow-up requirements.
- •A de novo target lesion in the femoral or popliteal arteries.
- •Target lesion must have angiographic evidence of ≥ 50% stenosis by operator visual estimate.
- •Target lesion must be ≤ 90 mm in length (one long lesion or multiple serial lesions) by operator visual estimate. Note: Multiple serial lesions are allowed provided that they can be treated as a single lesion with one balloon.
- •Target vessel must have an reference vessel diameter (RVD) of 4 mm to 6 mm by operator visual estimate.
- •After pre-dilatation, the target lesion is ≤ 70% residual stenosis, absence of a flow limiting dissection and treatable with a single balloon (lesion length ≤90 mm, limited to 100-mm balloon in EFS).
- •A patent inflow artery free from significant stenosis (≥ 50% stenosis) as confirmed by angiography.
- •At least one patent native outflow artery to the ankle or foot, free from significant stenosis (≥ 50% stenosis) as confirmed by angiography.
排除标准
- •Subjects will be excluded from the trial if any of the following criteria are met:
- •Subject has acute limb ischemia.
- •Subject has Rutherford classification of 0, 1, 5 or
- •Subject previously underwent any lower extremity percutaneous transluminal angioplasty (PTA) using a DCB within 3 months.
- •Subject has had prior vascular intervention within 2 weeks before the planned study index procedure or subject has planned vascular intervention within 30 days after the study index procedure.
- •Subject is pregnant and/or breast-feeding or intends to become pregnant during the time of the study OR subject is a male intending to father children within 60 days of index procedure.
- •Life expectancy less than 2 years.
- •Subject has a known allergy to contrast medium that cannot be adequately pre-medicated.
- •Subject is allergic to ALL antiplatelet treatments.
- •Subject has impaired renal function (i.e. serum creatinine level ≥ 2.5 mg/dl).
- •Subject is dialysis dependent.
- •Subject is receiving immunosuppressant therapy.
- •Subject has known or suspected active infection at the time of the index procedure.
- •Subject has platelet count < 100,000/mm3 or > 700,000/mm
- •Subject has white blood cell (WBC) count < 3,000/mm
- •Subject has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the index procedure.
- •Subject is diagnosed with coagulopathy that precludes treatment with systemic anticoagulation and/or dual antiplatelet therapy (DAPT).
- •Subject is unable to tolerate blood transfusions because of religious beliefs or other reasons.
- •Subject is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol.
- •Subject is known to be incarcerated, mentally incompetent and/or an alcohol or drug abuser.
- •Subject is participating in another investigational drug or medical device study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints from this study, or subject is planning to participate in such studies prior to the completion of this study.
- •Subject has had major surgical or interventional procedures unrelated to this study within 30 days prior to this study or has planned surgical or interventional procedures within 30 days of entry into this study.
- •Previous intervention at the lesion site including previous stenting within 3 cm of the target lesion or previous bypass surgery of the target lesion.
- •Previous treatment of the target vessel with thrombolysis or surgery.
- •Severe concentric calcification of the target lesion.
- •Target lesion involves an aneurysm or is adjacent to an aneurysm.
- •Target lesion requires treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy or re-entry devices.
- •Significant vessel tortuosity or other parameters prohibiting access to the target lesion.
- •Presence of thrombus in the target vessel.
- •Iliac inflow disease requiring treatment , unless the iliac artery disease is successfully treated first during the index procedure. Success is defined as ≤ 30% residual diameter stenosis without death or major complications.
- •Absence of at least one patent native outflow artery.
- •Presence of an aortic, iliac or femoral artificial graft.
- •Failure to cross the target lesion with a guide wire. Successful crossing of the target lesion occurs when the tip of the guide wire is distal to the target lesion without the occurrence of flow-limiting dissection or perforation.
- •Failure to successfully pre-dilate the target lesion. Successful pre-dilatation is defined as residual stenosis ≤ 70% with no flow-limiting dissection.
结局指标
主要结局
Peak paclitaxel plasma concentration
时间窗: Up to 30 days
Paclitaxel plasma levels will be assessed at baseline, immediately post-index procedure, at 1h, 2h, 4h, 12h (or upon discharge), and 30 days post-index procedure.
次要结局
- Embolic events of the index limb(30 days, 6, 12, 24, and 36 months)
- Evidence of Paclitaxel toxicity(At hospital discharge, 30 days)
- Major adverse events(30 days, 6, 12, 24, and 36 months)
- Index limb above the ankle amputation(30 days, 6, 12, 24, and 36 months)
- Major vascular complications(At hospital discharge, 30 days)
- Resting ankle brachial index(within 90 days of index procedure, and at 6, 12, 24 and 36 months post-index procedure)
- Change in 6-minute walk test(baseline, 30 days, 6, 12, 24, and 36 months)
- Continuous DUS Peak systolic velocity ratio (PSVR) as measured by Duplex ultrasound(30 days, 6, 12, 24, and 36 months)
- Late lumen loss(baseline, 6 months)
- Quality of life(baseline, 30 days, 6, 12, 24, and 36 months)
- Clinically-driven TLR(30 days, 6, 12, 24, and 36 months)
- Clinically-driven target vessel revascularization (TVR)(30 days, 6, 12, 24, and 36 months)
- Area under the drug concentration time curve(Up to 30 days)
- Technical success(At procedure)
- Device success(At procedure)
- Procedure success(At procedure up to 12 hours)
- Primary patency(6 months)
- Thrombolysis in Myocardial Infarction (TIMI)-defined major and minor bleeding(At hospital discharge, 30 days)
- All-cause death(30 days, 6, 12, 24, and 36 months)
- Change in Rutherford classification(baseline, 30 days, 6, 12, 24, and 36 months)
- Index limb below the ankle amputation(30 days, 6, 12, 24, and 36 months)
- Arterial thrombosis of the treated segment on angiography(30 days, 6, 12, 24, and 36 months)
研究者
研究点 (6)
Loading locations...
相似试验
招募中
不适用
IBS Titan™ Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System Clinical TrialInfrapopliteal LesionsCritical Limb IschemiaNCT05971394Biotyx Medical (Shenzhen) Co., Ltd.100
终止
不适用
The Pristine Post-Market StudyHemodialysis ComplicationHemodialysis Catheter InfectionHemodialysis Access FailureCentral Venous Catheter Related Bloodstream InfectionEnd Stage Renal DiseaseKidney Failure, ChronicNCT05228132C. R. Bard142
招募中
不适用
A Clinical Trial to Evaluate the Safety and Efficacy of IBS Angel in Patients With Pulmonary Artery StenosisPulmonary Artery StenosisNCT04973540Biotyx Medical (Shenzhen) Co., Ltd.82
Unknown
不适用
Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory GlaucomaGlaucomaNCT03639870Glaukos Corporation65
已完成
不适用
A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)Peripheral Arterial DiseaseCritical Limb IschemiaNCT05358353ReFlow Medical, Inc.130